Treatment of Low- or Intermediate-Grade DCIS of the Breast in Patients Aged 40 or Older
This protocol applies to a well-defined low-risk subset of ductal carcinoma in situ: patients aged 40 years or older whose tumour carries favourable pathological characteristics following surgery. The clinical evidence base for this scenario is drawn from dedicated prospective trials and major guideline bodies.
Clinical Scenario
Patients must meet all of the following criteria:
- Age 40 years or older
- Low- or intermediate-grade DCIS (nuclear grade 1 or 2)
- Tumour diameter less than 2.5 cm
- Negative (clear) resection margin
- Estrogen receptor-positive
- No comedo necrosis
Clinical trials have applied this same combination of patient age and pathological low-risk features consistently to define this sub-population.
Treatment Approach — Partial Overview
For patients meeting these low-risk criteria, current evidence supports a low-dose tamoxifen strategy. Guidelines recognise this as a reasonable option for appropriately selected patients in this setting.
Full dosing schedule, duration, and eligibility details are available in the structured protocol below.
References
DOI: 10.1093/jjco/hyae122
- The eligibility criteria in the two trials were almost the same (NG 1, NG 2, tumor diameter <2.5 cm and negative resection margin).
- The aim of this trial is to determine whether administration of low-dose tamoxifen (5 mg/day for 5 years) is non-inferior to RT (50 Gy in 25 fractions or 40.05 Gy in 15 fractions) for preventing IBTR in patients with low-risk characteristics (> 40 years old, low BRCA1/2 risk: Manchester Score < 10, mammographically detected unicentric and non-mass lesions, low- or intermediate-grade without comedo or necrosis, measuring <2.5 cm in diameter with a tumor-free margin of ≥3 mm, and ER-positive status) of DCIS.
- The NCCN guidelines state that low-dose tamoxifen (5 mg/day or 10 mg/every other day for 3 years) is a reasonable treatment option for patients who are symptomatic or unwilling to take the standard 20-mg dose.
- The TAM-01 trial was a phase III RCT conducted to verify the efficacy and safety of low-dose tamoxifen (5 mg/day for 3 years) after partial resection of the breast in patients with hormone-sensitive high-risk breast lesions.
View source ↗